1
|
Sercel AJ, Patananan AN, Man T, Wu TH, Yu AK, Guyot GW, Rabizadeh S, Niazi KR, Chiou PY, Teitell MA. Stable transplantation of human mitochondrial DNA by high-throughput, pressurized isolated mitochondrial delivery. eLife 2021; 10:63102. [PMID: 33438576 PMCID: PMC7864630 DOI: 10.7554/elife.63102] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Accepted: 01/12/2021] [Indexed: 12/31/2022] Open
Abstract
Generating mammalian cells with specific mitochondrial DNA (mtDNA)-nuclear DNA (nDNA) combinations is desirable but difficult to achieve and would be enabling for studies of mitochondrial-nuclear communication and coordination in controlling cell fates and functions. We developed 'MitoPunch', a pressure-driven mitochondrial transfer device, to deliver isolated mitochondria into numerous target mammalian cells simultaneously. MitoPunch and MitoCeption, a previously described force-based mitochondrial transfer approach, both yield stable isolated mitochondrial recipient (SIMR) cells that permanently retain exogenous mtDNA, whereas coincubation of mitochondria with cells does not yield SIMR cells. Although a typical MitoPunch or MitoCeption delivery results in dozens of immortalized SIMR clones with restored oxidative phosphorylation, only MitoPunch can produce replication-limited, non-immortal human SIMR clones. The MitoPunch device is versatile, inexpensive to assemble, and easy to use for engineering mtDNA-nDNA combinations to enable fundamental studies and potential translational applications.
Collapse
Affiliation(s)
- Alexander J Sercel
- Molecular Biology Interdepartmental Doctoral Program, University of California, Los Angeles, Los Angeles, United States
| | - Alexander N Patananan
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States
| | - Tianxing Man
- Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, Los Angeles, United States
| | - Ting-Hsiang Wu
- NanoCav, LLC, Culver City, United States.,NantBio, Inc, and ImmunityBio, Inc, Culver City, United States
| | - Amy K Yu
- Molecular Biology Interdepartmental Doctoral Program, University of California, Los Angeles, Los Angeles, United States
| | - Garret W Guyot
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States
| | - Shahrooz Rabizadeh
- NanoCav, LLC, Culver City, United States.,NantBio, Inc, and ImmunityBio, Inc, Culver City, United States.,NantOmics, LLC, Culver City, United States.,California NanoSystems Institute, University of California, Los Angeles, Los Angeles, United States
| | - Kayvan R Niazi
- NanoCav, LLC, Culver City, United States.,NantBio, Inc, and ImmunityBio, Inc, Culver City, United States.,California NanoSystems Institute, University of California, Los Angeles, Los Angeles, United States.,Department of Bioengineering, University of California, Los Angeles, Los Angeles, United States
| | - Pei-Yu Chiou
- Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, Los Angeles, United States.,California NanoSystems Institute, University of California, Los Angeles, Los Angeles, United States.,Department of Bioengineering, University of California, Los Angeles, Los Angeles, United States
| | - Michael A Teitell
- Molecular Biology Interdepartmental Doctoral Program, University of California, Los Angeles, Los Angeles, United States.,Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States.,California NanoSystems Institute, University of California, Los Angeles, Los Angeles, United States.,Department of Bioengineering, University of California, Los Angeles, Los Angeles, United States.,Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research University of California, Los Angeles, Los Angeles, United States.,Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States.,Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, United States
| |
Collapse
|
2
|
Argus JP, Wilks MQ, Zhou QD, Hsieh WY, Khialeeva E, Hoi XP, Bui V, Xu S, Yu AK, Wang ES, Herschman HR, Williams KJ, Bensinger SJ. Development and Application of FASA, a Model for Quantifying Fatty Acid Metabolism Using Stable Isotope Labeling. Cell Rep 2019; 25:2919-2934.e8. [PMID: 30517876 PMCID: PMC6432944 DOI: 10.1016/j.celrep.2018.11.041] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2018] [Revised: 07/23/2018] [Accepted: 11/09/2018] [Indexed: 12/20/2022] Open
Abstract
It is well understood that fatty acids can be synthesized, imported, and modified to meet requisite demands in cells. However, following the movement of fatty acids through the multiplicity of these metabolic steps has remained difficult. To better address this problem, we developed Fatty Acid Source Analysis (FASA), a model that defines the contribution of synthesis, import, and elongation pathways to fatty acid homeostasis in saturated, monounsaturated, and polyunsaturated fatty acid pools. Application of FASA demonstrated that elongation can be a major contributor to cellular fatty acid content and showed that distinct pro-inflammatory stimuli (e.g., Toll-like receptors 2, 3, or 4) specifically reprogram homeostasis of fatty acids by differential utilization of synthetic and elongation pathways in macrophages. In sum, this modeling approach significantly advances our ability to interrogate cellular fatty acid metabolism and provides insight into how cells dynamically reshape their lipidomes in response to metabolic or inflammatory signals. Argus et al. developed Fatty Acid Source Analysis (FASA), a model that quantifies cellular fatty acid synthesis, elongation, and import. FASA is used to demonstrate that elongation can be a major contributor to cellular fatty acid content and that different stimuli reprogram macrophage fatty acid elongation pathways in distinct ways.
Collapse
Affiliation(s)
- Joseph P Argus
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Moses Q Wilks
- Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, 149, 13(th) Street, Charlestown, MA 02129, USA
| | - Quan D Zhou
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA; Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
| | - Wei Yuan Hsieh
- Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Elvira Khialeeva
- Molecular Biology Institute, University of California, Los Angeles, 611 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Xen Ping Hoi
- Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Viet Bui
- Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90095, USA
| | - Shili Xu
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Amy K Yu
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Eric S Wang
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Harvey R Herschman
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, 611 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Kevin J Williams
- Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA
| | - Steven J Bensinger
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, 615 Charles E. Young Drive East, Los Angeles, CA 90095, USA.
| |
Collapse
|
3
|
Argus JP, Yu AK, Wang ES, Williams KJ, Bensinger SJ. An optimized method for measuring fatty acids and cholesterol in stable isotope-labeled cells. J Lipid Res 2016; 58:460-468. [PMID: 27974366 DOI: 10.1194/jlr.d069336] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2016] [Revised: 12/12/2016] [Indexed: 11/20/2022] Open
Abstract
Stable isotope labeling has become an important methodology for determining lipid metabolic parameters of normal and neoplastic cells. Conventional methods for fatty acid and cholesterol analysis have one or more issues that limit their utility for in vitro stable isotope-labeling studies. To address this, we developed a method optimized for measuring both fatty acids and cholesterol from small numbers of stable isotope-labeled cultured cells. We demonstrate quantitative derivatization and extraction of fatty acids from a wide range of lipid classes using this approach. Importantly, cholesterol is also recovered, albeit at a modestly lower yield, affording the opportunity to quantitate both cholesterol and fatty acids from the same sample. Although we find that background contamination can interfere with quantitation of certain fatty acids in low amounts of starting material, our data indicate that this optimized method can be used to accurately measure mass isotopomer distributions for cholesterol and many fatty acids isolated from small numbers of cultured cells. Application of this method will facilitate acquisition of lipid parameters required for quantifying flux and provide a better understanding of how lipid metabolism influences cellular function.
Collapse
Affiliation(s)
- Joseph P Argus
- Departments of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
| | - Amy K Yu
- Departments of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
| | - Eric S Wang
- Departments of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
| | - Kevin J Williams
- Departments of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
| | - Steven J Bensinger
- Departments of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 .,Departments of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095
| |
Collapse
|
4
|
York AG, Williams KJ, Argus JP, Zhou QD, Brar G, Vergnes L, Gray EE, Zhen A, Wu NC, Yamada DH, Cunningham CR, Tarling EJ, Wilks MQ, Casero D, Gray DH, Yu AK, Wang ES, Brooks DG, Sun R, Kitchen SG, Wu TT, Reue K, Stetson DB, Bensinger SJ. Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling. Cell 2015; 163:1716-29. [PMID: 26686653 DOI: 10.1016/j.cell.2015.11.045] [Citation(s) in RCA: 298] [Impact Index Per Article: 33.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Revised: 10/15/2015] [Accepted: 11/18/2015] [Indexed: 01/04/2023]
Abstract
Cellular lipid requirements are achieved through a combination of biosynthesis and import programs. Using isotope tracer analysis, we show that type I interferon (IFN) signaling shifts the balance of these programs by decreasing synthesis and increasing import of cholesterol and long chain fatty acids. Genetically enforcing this metabolic shift in macrophages is sufficient to render mice resistant to viral challenge, demonstrating the importance of reprogramming the balance of these two metabolic pathways in vivo. Unexpectedly, mechanistic studies reveal that limiting flux through the cholesterol biosynthetic pathway spontaneously engages a type I IFN response in a STING-dependent manner. The upregulation of type I IFNs was traced to a decrease in the pool size of synthesized cholesterol and could be inhibited by replenishing cells with free cholesterol. Taken together, these studies delineate a metabolic-inflammatory circuit that links perturbations in cholesterol biosynthesis with activation of innate immunity.
Collapse
Affiliation(s)
- Autumn G York
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Kevin J Williams
- Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Joseph P Argus
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Quan D Zhou
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Gurpreet Brar
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Laurent Vergnes
- Department of Human Genetics, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA
| | - Elizabeth E Gray
- Department of Immunology, University of Washington, 750 Republican Street, Box 358059, Seattle, WA 98109, USA
| | - Anjie Zhen
- Division of Hematology/Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; UCLA AIDS Institute and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Los Angeles, CA 90095, USA
| | - Nicholas C Wu
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Douglas H Yamada
- Immuno-Oncology Discovery Research; Janssen Research & Development, LLC, Spring House, PA 19477, USA
| | - Cameron R Cunningham
- Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Elizabeth J Tarling
- Division of Cardiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Moses Q Wilks
- Center for Advanced Medical Imaging Sciences, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
| | - David Casero
- Department of Pathology and Laboratory Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA
| | - David H Gray
- Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Amy K Yu
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Eric S Wang
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - David G Brooks
- Princess Margaret Cancer Center, Immune Therapy Program, University Health Network, Toronto, ON M5G 2M9, Canada; Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Ren Sun
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Scott G Kitchen
- Division of Hematology/Oncology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; UCLA AIDS Institute and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, Los Angeles, CA 90095, USA
| | - Ting-Ting Wu
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Karen Reue
- Department of Human Genetics, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - Daniel B Stetson
- Department of Immunology, University of Washington, 750 Republican Street, Box 358059, Seattle, WA 98109, USA
| | - Steven J Bensinger
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095, USA.
| |
Collapse
|
5
|
Abstract
PURPOSE To clarify the clinical features of delayed calcification of hydrogel intraocular lenses (IOLs) based on observation of a large case series. SETTING Ophthalmology department of 2 university teaching hospitals, Hong Kong, China. METHODS The first 44 patients with a known diagnosis of calcified IOL were recruited. Medical and ophthalmic histories were obtained. Surgical details, surgical complications, and visual acuity before and after IOL implantation were also retrieved. Patients then had a visual acuity test, a slitlamp examination of the features of the IOL calcification, and a fundus examination for clarity of view. RESULTS Forty-six eyes of 44 patients had IOL calcification. All had a Hydroview IOL. The onset was from 4 to 26 months after surgery. Ninety-three percent of eyes had generalized IOL calcification, and 96% had forceps marks on the IOL. Mean visual acuity deteriorated from 0.4 at 3 months to 0.13 at 19 months. Visual loss was more severe in patients with diabetes mellitus or ischemic heart disease and in those in which the IOL calcified earlier after implantation. CONCLUSION All cases of IOL calcification were delayed in onset. The presence of forceps marks may provide a clue to the pathogenesis. Bilateral but asymmetric involvement in 2 patients suggests that the IOL was involved in the pathogenesis. Affected patients lost an average of 2.8 Snellen lines of visual acuity. Some eyes progressed more rapidly; however, the modulating factors remain unknown.
Collapse
Affiliation(s)
- A K Yu
- Department of Ophthalmology, Queen Mary Hospital, Hong Kong, China.
| | | | | | | |
Collapse
|
6
|
Abstract
This paper describes the usefulness of electron microscopy in the investigation of the cause of opacification of an intraocular artificial lens (IOL), which affected both the anterior and posterior surfaces of the IOL. The explanted lenses were remarkably similar and were uniformly opaque, with "reticulated" surfaces under dissecting and ordinary light microscopes. TEM showed that the surfaces of the explanted lenses were irregular, and there was a layer of electron-dense granular deposits that extended to a depth of approximately 5 microm into the lens substance. SEM showed a "cerebriform" lens surface with elevated areas alternating with depressed crevices, which corresponded nicely to the TEM appearance. Energy-dispersive x-ray analysis showed that the deposit was composed of calcium, oxygen, and phosphorus, which was later shown to be calcium hydroxyapatite by x-ray diffraction study. Electron microscopy has proven to be an essential tool in the investigation of the cause of this mysterious outbreak of opacification of the surfaces of the artificial lenses. Apart from directly visualizing the lens surfaces in a 2- and 3-dimensional manner, it also provides information on the elemental composition of the deposit. Such findings enable the clinicians and manufacturer to search for the underlying pathogenesis of the abnormal calcium hydroxyapatite crystals deposit.
Collapse
Affiliation(s)
- T W Shek
- Department of Pathology, Queen Mary Hospital, Hong Kong.
| | | | | | | |
Collapse
|
7
|
|
8
|
van Dijk K, Gupta V, Yu AK, Jansen JA. Measurement and control of interface strength of RF magnetron-sputtered Ca-PO coating on Ti-6Al-4V substrates using a laser spallation technique. J Biomed Mater Res 1998; 41:624-32. [PMID: 9697036 DOI: 10.1002/(sici)1097-4636(19980915)41:4<624::aid-jbm15>3.0.co;2-e] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In previous studies, an RF magnetron sputter technique was developed for the production of thin calcium phosphate coating. Several deposition parameters were found to influence the growth rate and the stoichiometry of the coatings. For instance, deposition with additional oxygen pressure decreased the Ca to P ratio of the coatings to 1.67. For application of these coatings on actual Ti implants, it is important to know their adhesive tensile strength with the implant surface and how it varies with the deposition parameters. Motivated by these goals, the aim of this study was to measure the adhesive tensile strength of these coatings with Ti substrates and to study its variation with the deposition parameters. Since most mechanical characterization methods are incapable of providing a direct measure of the interface's fundamental strength, a novel laser spallation experiment was used to accomplish this task. In this experiment, a compressive stress pulse is generated on the back side of a substrate by impinging a 3-ns long Nd:YAG laser pulse. The stress pulse propagates through the substrate and is reflected into a tensile stress wave from the free surface of the coating deposited on its front surface. The returning tensile pulse pries off the coating if its amplitude is high enough. The peak interface tensile stress is computed by using the optically recorded free surface displacement of the coating. Because interface decohesion is accomplished at a strain rate of almost 10(7) s-1, all inelastic processes essentially are suppressed and the measured value essentially is the intrinsic tensile strength of the interface. Tensile strength values in the range of 500-900 MPa were recorded for the interfaces between sputter-deposited calcium-phosphate coatings and Ti substrates. To confirm the locus of failure, the spalled spots were examined using SEM and EDS. The variation in the measured values was related to the changes in the deposition conditions.
Collapse
Affiliation(s)
- K van Dijk
- University of Nijmegen, Department of Biomaterials, The Netherlands
| | | | | | | |
Collapse
|